Back
PTX
Prescient Therapeutics Limited
🇦🇺 ASX
🧬 BIOTECHNOLOGY
👑 Overview
📈 Performance
💵 Cost
🤓 Advanced
👨👩👧👦 Community
📈
-6.44%
Annual Growth
5 years average annual capital growth
💵
$ 500
Minimum Order
Due to regulatory requirements
🌏
20
Pearlers Invested
Since January 2020
👑 Overview
Key information
🔎 Fund Overview
Prescient Therapeutics Ltd. is a biopharmaceutical company, which engages in the discovery and development of novel immunotherapeutic products for the treatment of chronic infectious diseases and cancer. The company is headquartered in Melbourne, Victoria. The firm is developing personalized medicine approaches to cancer, including targeted and cellular therapies. Its product pipeline includes PTX-100, PTX-200, OmniCAR, CellPryme-M and CellPryme-A. PTX-100 has completed Phase Ib expansion cohort study in relapsed and refractory T cell lymphomas. PTX-200 is a PH domain inhibitor that inhibits a tumor survival pathway, Akt. OmniCAR is a universal immune receptor platform being developed to enable controllable T-cell activity and multi-antigen targeting with a single-cell product. CellPryme-M technology enhances adoptive cell therapy performance by shifting T and NK cells towards a central memory phenotype, improving persistence, and increasing the ability to find and penetrate tumors. CellPryme-A is an adjuvant therapy designed to be administered to patients alongside cellular immunotherapy to help them overcome a suppressive tumor microenvironment.
📈 Performance
Price History
-43.43%
1M
1Y
10Y
Graph
Table
Unsure how much or often to invest?
🗓️ Investing frequency calculator
Determine the investment frequency needed to reach your goals
Try it out →💵 Investing amount calculator
Determine the recurring investment needed to reach your goals
Try it out →⏱️ Investing duration calculator
Determine how long you will need to invest to reach your goals
Try it out →💵 Costs
💼
N/A
Management Fee
Included in unit price, not charged by Pearler
💸
Want to know the long term costs?
Calculate the historic long term costs to hold your investments
💸 Net fee calculator🤓 Advanced information
Technical Info
💰 Price*
$0.04
*Price may be up to 24 hours old
👩👩👦 Community Insights
How our community is investing
🌏 Pearlers invested in PTX
20
📊 Total Capital Earnings
$6K
🔃 Average investment frequency
32 weeks
💵 Average investment amount
$1,447
⏰ Last time a customer invested in PTX
12 days
PTX investor breakdown
💵 Income of investors
More than 200k
150k - 200k
100k - 150k
17%
50k - 100k
35%
Less than 50k
39%
👶 Age of investors
18 - 25
26 - 34
45%
35 - 90
50%
🙋 Legal gender of investors
Female
60%
Male
40%
Pearlers who invest in PTX also invest in...
VAS.AX was created on 2009-05-04 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard Australian Shares Index ETF seeks to track the return of the S&P/ASX 300 Index before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
9.09%
📊 Share price
$110.92 AUD
💸 FINANCIALS
🧱 MATERIALS
⛳️ DIVERSIFIED
📈 HIGH PRICE GROWTH
🇦🇺 AUSTRALIA
IVV.AX was created on 2000-05-15 by iShares. The fund's investment portfolio concentrates primarily on large cap equity. The Fund aims to provide investors with the performance of an index, before fees and expenses. The index is designed to measure the performance of large capitalisation US equities.
🙌 Performance (5Yr p.a)
22.50%
📊 Share price
$66.50 AUD
📈 HIGH PRICE GROWTH
🇺🇸 UNITED STATES
VDHG.AX was created on 2017-11-20 by Vanguard. The fund's investment portfolio concentrates primarily on target outcome asset allocation. Vanguard Diversified High Growth Index ETF seeks to track the weighted average return of the various indices of the underlying funds in which it invests, in proportion to the Strategic Asset Allocation, before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
7.43%
📊 Share price
$72.85 AUD
⛳️ DIVERSIFIED
🌏 GLOBAL
VGS.AX was created on 2014-11-18 by Vanguard. The fund's investment portfolio concentrates primarily on total market equity. Vanguard MSCI International Shares Index ETF seeks to track the return of the MSCI World ex-Australia Index (with net dividends reinvested) in Australian dollars before taking into account fees, expenses and tax.
🙌 Performance (5Yr p.a)
17.46%
📊 Share price
$148.51 AUD
🌏 GLOBAL
⛳️ DIVERSIFIED
🤖 TECHNOLOGY
📈 HIGH PRICE GROWTH
XRO
Xero Ltd. engages in the provision of online business solutions for small businesses and advisory services. The company operates a global small business platform which includes a core accounting solution, payroll, workforce management, expenses, and projects. Its segments include Australia and New Zealand (ANZ), and International. The company also has an ecosystem of connected apps and connections to banks and other financial institutions helping small businesses access a range of solutions from within its open platform to help them run their business and manage their finances. Its cloud-based platform allows small business customers and partners to access real-time data to manage their businesses, support compliance with accounting and tax requirements, collaborate, and connect to other parties such as banks, financial services partners, or ecosystem apps. The features and tools of its software platform include pay bills, claim expenses, bank connections, accept payments, and others. Its brands include Planday, WorkflowMax, Hubdoc, TaxCycle, and Tickstar.
🙌 Performance (5Yr p.a)
13.67%
📊 Share price
$158.89 AUD
📈 HIGH PRICE GROWTH
🤖 TECHNOLOGY
Want more shares? Try these...
Prescient Therapeutics Ltd. is a biopharmaceutical company. The company is headquartered in South Melbourne, Victoria. The company is also focused on developing therapies for a range of cancers, using CAR-T and targeted therapy approaches. The firm has a broad pipeline of cancer treatments, comprising CAR-T and targeted therapies, for cancers. Its product pipeline includes OmniCAR, PTX-100 and PTX-200. OmniCAR is a universal immune receptor platform enabling controllable T-cell activity and multi-antigen targeting with a single cell product. PTX-100 is a Phase Ib clinical candidate that block the cancer growth enzyme known as geranylgeranyl transferase-1. PTX-100 is in a pharmacokinetic basket study of hematological and solid malignancies, focusing on cancers with Ras and RhoA mutations. PTX-200 is in Phase Ib/IIa clinical candidate. PTX-200 is a novel PH domain inhibitor that inhibits an important tumor survival pathway known as Akt.
